Development. Validation. Accessibility.

📢 New from BLOODPAC: The BLOODPAC Dictionary is now live — a centralized, community-driven resource featuring key terms developed by the community, for the community.

This dictionary brings together terminology from several published lexicons authored by BLOODPAC working groups, helping to create clarity and consistency across the liquid biopsy field. Whether you're new to the space or deep in the work, this tool is here to support shared understanding and better collaboration.

📖 Explore the BLOODPAC Dictionary today → https://lnkd.in/ghsTSAzr

👏 Thank you to everyone who joined us yesterday for our Early Detection Summer Seminar!

We’re already working to bring you something special this fall, mark your calendars for BLOODPAC’s 𝗡𝗲𝘄 𝗙𝗿𝗼𝗻𝘁𝗶𝗲𝗿𝘀 𝗦𝗲𝗺𝗶𝗻𝗮𝗿!

This year’s theme: 🎯 𝘕𝘦𝘸 𝘍𝘳𝘰𝘯𝘵𝘪𝘦𝘳𝘴 𝘪𝘯 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘚𝘦𝘭𝘦𝘤𝘵𝘪𝘰𝘯: 𝘉𝘦𝘺𝘰𝘯𝘥 𝘋𝘕𝘈 𝘔𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘴

We’ll bring together leading experts to explore how multimodal data and liquid biopsy can shape the future of therapy selection.

Stay tuned for speaker announcements and registration details.

💬 How do you define “elevated risk” when a test covers more than one cancer?

If a patient has a BRCA1 mutation, are they at high risk for every cancer in a multi-cancer detection (MCD) panel?

Our recent paper highlights just how ambiguous risk definitions can get, and why it’s time for shared, clinically grounded terminology.

👉 Check out the full paper here to see how the BLOODPAC Early Detection and Screening Working Group is helping bring clarity to this evolving space: https://lnkd.in/gH4HQ-xe